CONCURRENT CARBOPLATIN WITH RADIOTHERAPY IN T2 LARYNGEAL CANCER
|
Accession number;04A0146764
|
| Title;CONCURRENT CARBOPLATIN WITH RADIOTHERAPY IN T2 LARYNGEAL CANCER |
| Author;
INOUE HITOSHI
(Tokyo Medical Univ., JPN)
KIDA AKINORI
(Nihon Univ., School of Medicine, Itabashi Hosp.)
SUZUKI MAMORU
(Tokyo Medical Univ., JPN)
YOSHIDA TOMOYUKI
(Tokyo Medical Univ., JPN)
FURUSAKA TOORU
(Nihon Univ., Surugadai Hosp.)
ENDO SOHEI
(Nihon Univ., School of Medicine, Itabashi Hosp.)
NAKAI TAKAHISA
(Nihon Univ., Surugadai Hosp.)
|
Journal Title;Head and Neck Cancer
|
Journal Code:Y0503A
|
ISSN:0911-4335
|
|
VOL.28;NO.1;PAGE.226-230(2002)
|
| Figure&Table&Reference;TBL.3, REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A combination of carboplatin (CBDCA) therapy and radiotherapy was used in T2 laryngeal cancer. The subjects were 34 untreated patients with T2 laryngeal cancer, who were enrolled during the period from May 1998 to April 2000. All the patients were male, and their average age was 64.4 years. The dose of CBDCA was properly adjusted so that the AUC would be either 1.5 or 2.0. CBDCA therapy was conducted once a week for four weeks. As a rule, radiotherapy was administered at a dose of 2Gy, with a total of 60Gy to be given to each patient. Of the 34 patients, 29 were eligible for evaluation. Twenty-five of the 29 patients demonstrated complete response (CR) (86.2%). The larynx was preserved in 25 of these 29 patients (86.2%). The complete response rate was 81.8% in those who were placed on CBDCA therapy with an AUC of 1.5, and 88.9% in those with an AUC of 2.0. Regarding hematological toxicity, grade 3 leukocytopenia was recognized in three patients, while symptoms of thrombocytopenia severer than grade 3 were rarely observed. Accordingly, CBDCA therapy with an AUC of 2.0 reflects the optimum dose of CBDCA. The combination of CBDCA therapy and radiology is considered to be an effective treatment for T2 laryngeal cancer. (author abst.) |
|
|
|
Related Articles;
|
|
